DK2818482T3 - Farmaceutisk sammensætning til behandling af cancer - Google Patents

Farmaceutisk sammensætning til behandling af cancer Download PDF

Info

Publication number
DK2818482T3
DK2818482T3 DK13751278.6T DK13751278T DK2818482T3 DK 2818482 T3 DK2818482 T3 DK 2818482T3 DK 13751278 T DK13751278 T DK 13751278T DK 2818482 T3 DK2818482 T3 DK 2818482T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
cancer treatment
cancer
treatment
pharmaceutical
Prior art date
Application number
DK13751278.6T
Other languages
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of DK2818482T3 publication Critical patent/DK2818482T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK13751278.6T 2012-02-21 2013-02-21 Farmaceutisk sammensætning til behandling af cancer DK2818482T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035484 2012-02-21
PCT/JP2013/054337 WO2013125636A1 (ja) 2012-02-21 2013-02-21 癌の治療及び/又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
DK2818482T3 true DK2818482T3 (da) 2019-07-15

Family

ID=49005813

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13751278.6T DK2818482T3 (da) 2012-02-21 2013-02-21 Farmaceutisk sammensætning til behandling af cancer

Country Status (17)

Country Link
US (1) US9273130B2 (da)
EP (1) EP2818482B1 (da)
JP (1) JP6187255B2 (da)
KR (1) KR102009238B1 (da)
CN (1) CN104169303B (da)
AU (1) AU2013223143B2 (da)
BR (1) BR112014021101A2 (da)
CA (1) CA2864864C (da)
DK (1) DK2818482T3 (da)
ES (1) ES2739612T3 (da)
HU (1) HUE044611T2 (da)
IN (1) IN2014KN01713A (da)
MX (1) MX360208B (da)
PL (1) PL2818482T3 (da)
PT (1) PT2818482T (da)
RU (1) RU2632645C2 (da)
WO (1) WO2013125636A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2322221T3 (pl) 2008-08-05 2015-01-30 Toray Industries Kompozycja farmaceutyczna do leczenia i zapobiegania raka
ES2471379T3 (es) 2008-08-05 2014-06-26 Toray Industries, Inc. Método para detectar el cáncer
JP5906739B2 (ja) * 2010-02-04 2016-04-20 東レ株式会社 癌の治療及び/又は予防用医薬組成物
RU2624040C2 (ru) * 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Способ обнаружения рака поджелудочной железы
HUE030130T2 (en) * 2011-08-04 2017-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び/又は予防用医薬組成物
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego
ES2656620T3 (es) * 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado
HUE043162T2 (hu) 2012-07-19 2019-08-28 Toray Industries Eljárás rák detektálására
EP2876447B1 (en) 2012-07-19 2019-11-20 Toray Industries, Inc. Method for detecting cancer
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
PT3031826T (pt) 2013-08-09 2019-01-18 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
BR112018067458A2 (pt) 2016-03-04 2019-01-02 Abmuno Therapeutics Llc anticorpos para tigit
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
WO2018079740A1 (ja) 2016-10-28 2018-05-03 東レ株式会社 癌の治療及び/又は予防用医薬組成物
EP3777888A4 (en) 2018-03-30 2021-12-01 Toray Industries, Inc. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
MX2021015221A (es) 2019-06-13 2022-03-17 Bolt Biotherapeutics Inc Compuestos de aminobenzazepina, inmunoconjugados y usos de estos.
BR112022006001A2 (pt) 2019-09-30 2022-07-12 Bolt Biotherapeutics Inc Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado
IL292396A (en) 2019-10-25 2022-06-01 Bolt Biotherapeutics Inc Thianozapine immunoconjugates and uses thereof
WO2021182572A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
US20230129035A1 (en) 2020-03-12 2023-04-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2021182571A1 (da) 2020-03-12 2021-09-16
CA3175279A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2021182570A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
KR20230019152A (ko) 2020-06-02 2023-02-07 아르커스 바이오사이언시즈 인코포레이티드 Tigit에 대한 항체
KR20230051189A (ko) 2020-08-13 2023-04-17 볼트 바이오테라퓨틱스 인코퍼레이티드 피라졸로아제핀 면역접합체, 및 그의 용도
KR20240024803A (ko) 2021-06-23 2024-02-26 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
CN117545508A (zh) 2021-06-23 2024-02-09 东丽株式会社 用于癌的治疗和/或预防的药品
MX2024001099A (es) 2021-07-27 2024-02-23 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.
KR20240041917A (ko) 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4378476A1 (en) 2021-07-27 2024-06-05 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
EP4422697A1 (en) 2021-10-29 2024-09-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
PT1069185E (pt) 1998-04-03 2011-08-11 Chugai Pharmaceutical Co Ltd Anticorpo humanizado contra factor tecidual (tf) humano e processo para construção de um anticorpo humanizado
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
AU4185100A (en) 1999-04-02 2000-10-23 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1224285A4 (en) 1999-10-29 2004-12-08 Human Genome Sciences Inc 27 HUMAN SECRETED PROTEINS
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
EP1391511B1 (en) 2001-05-11 2008-06-11 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody lambda light chain gene
EP1516049A4 (en) 2001-05-11 2006-01-11 Corixa Corp COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
EP2311870A1 (en) 2002-11-26 2011-04-20 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
CA2524173A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
JP2008506352A (ja) 2004-01-26 2008-03-06 デビオビジョン・インコーポレーテッド 新生物特異的ポリペプチド及びその使用
US7598350B2 (en) 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
CA2562953A1 (en) 2004-03-30 2005-10-13 Glaxo Group Limited Humanized and chimeric anti-osm antibodies
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
KR20190016616A (ko) 2005-01-21 2019-02-18 제넨테크, 인크. Her 항체의 고정 용량 투여법
EP1849002A4 (en) 2005-02-18 2008-08-20 Childrens Medical Center CYR61 AS A BIOMARKER FOR THE DIAGNOSIS AND PROGNOSIS OF CANCERS OF EPITHELIAL ORIGIN
NZ560976A (en) 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
CA2642342A1 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
EP3106875B1 (en) 2007-10-25 2020-04-29 Toray Industries, Inc. Method for detection of cancer
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
SI2254571T1 (sl) 2008-03-18 2015-10-30 Genentech, Inc. Kombinacije konjugata protitelo proti HER2-zdravilo in kemoterapevtskih sredstev ter postopki uporabe
CN102170797B (zh) * 2008-07-31 2014-02-19 西诺米克斯公司 包含甜味增强剂的组合物和它们的制备方法
KR20160127146A (ko) 2008-08-05 2016-11-02 도레이 카부시키가이샤 면역 유도제
PL2322221T3 (pl) 2008-08-05 2015-01-30 Toray Industries Kompozycja farmaceutyczna do leczenia i zapobiegania raka
ES2471379T3 (es) 2008-08-05 2014-06-26 Toray Industries, Inc. Método para detectar el cáncer
JP5734978B2 (ja) 2009-08-19 2015-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Ffpe材料におけるインテグリン複合体検出のための抗体
CN102648280B (zh) 2009-09-22 2014-10-08 普罗拜奥根股份公司 生产含有特定聚糖结构之分子的方法
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга
CA2788715C (en) * 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CN109925511B (zh) * 2010-02-04 2024-03-19 东丽株式会社 用于癌的治疗和/或预防的药物
EP2532364B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer
EP2532680B1 (en) * 2010-02-04 2015-04-29 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
HUE030742T2 (en) 2010-02-04 2017-06-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
JP5906739B2 (ja) 2010-02-04 2016-04-20 東レ株式会社 癌の治療及び/又は予防用医薬組成物
KR101271964B1 (ko) 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
KR101576174B1 (ko) 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
JP2012035484A (ja) 2010-08-06 2012-02-23 Tombow Pencil Co Ltd 塗膜転写具
RU2624040C2 (ru) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Способ обнаружения рака поджелудочной железы
CN103717740B (zh) 2011-08-04 2015-10-21 东丽株式会社 癌的治疗和/或预防用药物组合物
HUE030130T2 (en) 2011-08-04 2017-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer
ES2656620T3 (es) 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego

Also Published As

Publication number Publication date
KR102009238B1 (ko) 2019-08-09
PL2818482T3 (pl) 2019-11-29
HUE044611T2 (hu) 2019-11-28
CA2864864C (en) 2020-05-12
CN104169303B (zh) 2018-05-29
MX360208B (es) 2018-10-24
EP2818482B1 (en) 2019-05-22
JPWO2013125636A1 (ja) 2015-07-30
RU2632645C2 (ru) 2017-10-06
BR112014021101A2 (pt) 2022-03-22
CN104169303A (zh) 2014-11-26
JP6187255B2 (ja) 2017-08-30
EP2818482A4 (en) 2015-10-07
AU2013223143B2 (en) 2017-12-21
AU2013223143A1 (en) 2014-09-11
US9273130B2 (en) 2016-03-01
CA2864864A1 (en) 2013-08-29
PT2818482T (pt) 2019-08-06
KR20140130668A (ko) 2014-11-11
US20150004171A1 (en) 2015-01-01
EP2818482A1 (en) 2014-12-31
WO2013125636A1 (ja) 2013-08-29
IN2014KN01713A (da) 2015-10-23
RU2014138040A (ru) 2016-04-10
ES2739612T3 (es) 2020-02-03
MX2014009748A (es) 2014-11-14

Similar Documents

Publication Publication Date Title
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
DK2694038T3 (da) Farmaceutisk sammensætning
DK2914248T4 (da) Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme
DK2900061T3 (da) Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
DK2914965T3 (da) Aflukker til biologiske mikroobjekter
BR112015002738A2 (pt) composto , e , composição farmacêutica
DK2768479T3 (da) Hjælpestoffer til nikotin-indeholdende terapeutiske sammensætninger
FR2997014B1 (fr) Composition sterile dermo-injectable
DK3677252T3 (da) Doseringsregimer for echinocandin-klasse forbindelser
BR112014028424A2 (pt) compostos de pirimidina para o tratamento de câncer
BR112014032798A2 (pt) composição
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
DK2872497T4 (da) Chromanyl-derivater til behandling af mitokondriel sygdom
DK2897594T3 (da) Farmaceutisk sammensætning
DK2815752T3 (da) Oral farmaceutisk sammensætning
DK3511004T3 (da) Kombineret præparat til behandling af cancer
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
DK3052102T3 (da) Sammensætninger til behandling af cancere
ES2721400T8 (es) Composición de Diclofenaco
BR112015010797A2 (pt) compostos aniônicos substituídos, e, composição farmacêutica
DK2812013T3 (da) Formulering til behandling af IBS